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Background: Female fertility depends on adequate nutrition and energy reserves, suggesting a correlation
between the metabolic reserve and reproductive capacity. Leptin regulates body weight and energy homeostasis.
The aim of this study was to investigate whether estradiol or FSH alone has a direct effect on the production of
leptin.
Methods: A total of 64 patients submitted to controlled ovarian hyperstimulation with recombinant FSH for
assisted reproduction and 20 patients using estradiol valerate for endometrial preparation for oocyte donation
treatment were included in the study. All patients used GnRH analogues before starting treatment to achieve
pituitary suppression. Blood samples for hormonal measurements were collected before starting and after
completing the respective treatments. Data were analyzed statistically by the chi-square test, Student’s t-test and
Pearson’s correlation test.
Results: We observed an elevation of serum leptin levels secondary to the increase in estradiol, in the absence of
influence of any other ovarian or pituitary hormone. The rising rate of leptin levels was higher in women treated
with recombinant FSH, which also had higher levels of estradiol, than in those treated with estradiol valerate.
Conclusions: This study demonstrates a correlation between serum levels of estradiol and leptin, suggesting that
estradiol is an important regulator of leptin production and that its effects can be amplified by its association with
FSH.
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The relationship between body fat and the reproductive
process has been studied for many years. Fertility
depends on a correct nutrition and energy reserves, what
creates a correlation between the metabolic reserve and
reproductive capacity [1]. Women with extreme dietetic
restrictions and those who are overweight show altera-
tions in the reproductive axis. Obese women also have
an early menarche than those with normal weight. This
can be explained by the fact that menstrual cycle initi-
ates only when the body weight reaches a critical mass,
around 48 Kg or contains approximately 22% of body fat
and obese women enter this critical weight range at a
younger age [2]. Irregular menstrual cycles are frequent* Correspondence: selmogeber@origen.com.br
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reproduction in any medium, provided the oramong women too thin, those with eating disorders such
as bulimia or nervous anorexia and athletes submitted
to long-term exercises [3].
Leptin is a protein codified by the obesity gene (ob),
secreted by the adipocytes [4], which acts in the Central
Nervous System as a signal to regulate body weight and
energy homeostasis [5,6]. Initially, leptin was considered
an anti-obesity hormone [7], but experimental evidences
have shown that this molecule also participates in many
metabolic and endocrine processes, including the repro-
ductive function [8,9]. The presence of leptin receptors
at all levels of the hypothalamic-pituitary-ovarian axis
indicates a correlation between nutrition and re-
production, possibly through complex paracrine and/or
endocrine interactions [10].
Although leptin receptors have been demonstrated in
human ovaries, there is no information concerning lep-
tin effects on follicular cells [11]. Contradictory resultstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and follicle-stimulating hormone (FSH) on leptin pro-
duction by adipocytes [12-15]. Therefore the aim of this
study was to investigate whether estradiol or FSH has a
direct effect on the production of leptin.
Methods
Patients
This prospective study included a total of 84 patients
who underwent infertility treatment through assisted
reproduction technique at ORIGEN, Centre of Repro-
ductive Medicine, Belo Horizonte, Brazil. This study was
approved by our local ethics committee, according to
Brazilian ethics and legal regulation, and all patients
signed an Informed Consent Form. Patients with tubal
or male factor infertility who had serum FSH concentra-
tions <15 IU/l on day 3 of the menstrual cycle were sub-
mitted to controlled ovarian superovulation for IVF/ICSI
(GnRHa/FSH Group) (n = 64). Patients with poor ovar-
ian reserve, i.e., with serum FSH concentrations >15 IU/
l and serum estradiol levels <60 pg/ml on day 3 of the
menstrual cycle were submitted do oocyte donation
(OD) treatment (GnRHa/E2 Group) (n = 20). Patients
with endocrine disorders were not included. Body Mass
Index (BMI) was calculated using the patient’s body
weight (Kg) divided by the square of their height
(meters). Women were considered obese when BMI was
>30 kg/m2. All patients had normal glucose levels.
Controlled ovarian stimulation
All patients of group 1 (GnRHa/FSH) submitted to IVF/
ICSI had the same long protocol for controlled ovarian
stimulation using the same hormones and the same cri-
teria for dose tailoring. Treatment started with subcuta-
neous administration of 3.6 mg of GnRHa (Goserelin,
Zoladex; Zeneca, Brazil) for suppression of pituitary
function on day 2 of the menstrual cycle. To confirm pi-
tuitary down-regulation, serum estradiol (E2) levels and
vaginal ultrasound were performed~ 10 days later. If the
estradiol concentration was <30 pg/ml and the ultra-
sound showed an endometrial thickness of <3 mm, pitu-
itary suppression was confirmed. Otherwise, serum
estradiol and vaginal ultrasound were repeated every
other day until suppression was achieved [16].
After confirmation of suppression, patients were supero-
vulated with daily subcutaneous injections of recombinant
FSH (rFSH – GonalF – Serono – Brazil). The starting
dose of rFSH was defined according to patient’s age, i.e.,
225 IU for <35 years old, 300 IU for 35 to 37 years old
and 375 IU for> 37 years old. The dose was adjusted
according to the ovarian response measured by E2 levels
and follicular growth monitored by vaginal ultrasound
(Tosbee- Toshiba- Japan). Recombinant hCG (rhCG- 250
mcg – Ovidrel – Serono – Brazil) was given when at leasttwo follicles reached a mean size of 17 mm with corre-
sponding E2 levels (~ 200 pg/mL per follicle) [17]. Oocyte
retrieval was performed ~34 hours after rhCG injection by
vaginal ultrasound guided aspiration.
Endometrial preparation
All patients in group 2 (GnRHa/E2) submitted to oocyte
donation had the same endometrial preparation. Treat-
ment started with pituitary suppression, as described for
patients in group 1 (GnRHa/FSH). After pituitary down-
regulation was confirmed, estradiol valerate (E2V – Pri-
mogyna – Bayer – Brazil) was given to the patients for
endometrial preparation. Patients started with 2 mg/day
from day 1 – 5, then the dose was increased to 4 mg/
day from day 6 – 10, and increased to 6 mg/day from
day 11 until 12 weeks of pregnancy. After 15 days of
treatment, endometrial preparation was confirmed if E2
levels were >250 pg/ml and vaginal ultrasound showed
an endometrial thickness >8 mm [18].
Hormone assays
Blood samples for FSH, estradiol and leptin measure-
ments were collected between 8:00 and 10:00 am. The
first collection occurred on the day pituitary suppression
was confirmed for both groups. For patients of group 1,
the second blood collection was performed on the last
day of controlled ovarian stimulation, i.e., when patients
presented the maximum serum levels of estradiol. For
patients of group 2, the second blood collection was per-
formed on the day of the insemination (IVF or ICSI), i.
e., when they had maximum serum levels of estradiol,
and before progesterone administration.
For FSH measurements we used immunometric assays
based on enhanced luminescence (AmerliteFSH assay –
Amersham International plc – UK). The inter- and
intra-assay coefficients of variation were 7.5 and 6.0% re-
spectively. The results were expressed as IU/l. Estradiol
was measured using a competitive immunoassay based
on enhanced luminescence (AmerliteEstradion-60 assay;
Amersham International). The results were expressed as
pg/ml. The inter- and intra-assay coefficients of variation
were 9.1 and 8.0% respectively.
Leptin was measured in all serum samples in duplicate
using a radioimmunoassay method and all samples were
assayed in the same batch. The kits (Linco Research – St
Charles – USA) contained human leptin antibody prepared
in rabbit and raised against highly purified human leptin
and standards and tracer prepared with human leptin. The
results were expressed as ng/ml. The inter- and intra-assay
coefficients of variation were 6.2 and 7.1% respectively.
Statistics
Shapiro-Wilk test was used to assess the normality of
continuous data. The Chi-square test was applied to
Table 1 Patient characteristics according to the type of
hormonal treatment
GnRHa/FSHn=64 GnRHa/E2n= 20 p
Age (years) 34.3 ± 3.7 (27 – 42) 42 ± 4.8 (31 – 50) 0.0001a
BMI (Kg/m2) 23 ± 5.1 23.3 ± 4.1 0.25 a
Obese 17.2% 15% 0.24 b
Values are expressed in mean ± sd (range).
aStudent’s t test for paired samples.
bchi-square test.
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patients. Mann-Whitney’s test was performed to com-
pare the medians of BMI, estradiol, leptin, and leptin
rate. The Pearson correlation test was used to assess the
relationship between the hormones. We calculated the
leptin rate (LR) as follows: LR =LA/LB x100, where LA
corresponds to the leptin levels after treatment and LB
to the leptin levels before treatment. Differences were
considered significant when p< 0.05. Descriptive data
were expressed as mean ± SD or as median (interquartile
range) for normally and non-normally distributed data,
respectively.
Results
All 84 patients selected in this study completed the
treatment and had no adverse effects. The mean age
(±SD) of the patients submitted to IVF/ICSI was
34.3 ± 3.7 years (range 27 – 42) and for the patients sub-
mitted to OD was 42 ± 4.8 years (range 31 – 50). In the
GnRHa/FSH group the mean BMI was 23 ± 5.1 and 11
patients (17.2%) were obese, in the GnRHa/E2 group the
mean BMI was 23.3 ± 4.1 and 3 patients (15%) were
obese (Table 1).
When we compared the serum leptin levels according
to the BMI, we observed that leptin levels were signifi-
cantly higher in obese than in non-obese patients, both
before (10.9 ± 3.3 and 8.8 ± 4.2, respectively – p = 0.017)
and after treatment (26.3 ± 11.7 and 13.5 ± 7.5, respect-
ively – p = 0.0047).
In both GnRHa/FSH and GnRHa/E2groups, both
serum estradiol and leptin levels were significantly
higher after than before starting treatment (Table 2).
Leptin levels presented by these groups were similar,
both before and after treatment (p = 0.8 and 0.7,Table 2 Serum Leptin and estradiol levels measured before a
Leptin before treatment Leptin after treatment
GnRHa/FSH 10.4 ± 6.8 15.7 ± 9.6
n = 64 (2.1 - 45) (4.6 – 46.2)
GnRHa/E2 11.1 ± 9,9 14.5 ± 12.51
n = 20 (2.3 – 40.4) (3 – 53.8)
Values are expressed as mean± sd (range).
Data were analyzed using Student’s t test for paired samples.respectively). Estradiol levels measured after treatment
were significantly higher in the GnRHa/FSH group than
in the GnRHa/E2 group (p = 0.009) (Table 1).
Pearson’s correlation analysis demonstrated significant
correlation between FSH or estradiol, and leptin serum
levels. Correlation coefficients of 0.72 and 0.92 were
observed for the serum levels of leptin detected before
and after treatment in the GnRHa/FSHgroup and in the
GnRHa/E2 group, respectively. Also, this result shows
that the final levels of leptin are directly related to the
initial ones.
The leptin rate was calculated to evaluate the rising
rate of leptin levels from the first to the second analysis.
We detected similar leptin rates between obese and
non-obese patients (167.4 ± 93.4 and 158 ± 48.9, respect-
ively). The mean leptin rate in the GnRHa/FSH group
was 159.6 ± 58.1 (range 74.2 – 408.8) and 136.7 ± 34.2
(range 65.4 – 213.7) in the GnRHa/E2 group. The differ-
ence between these groups was statistically significant
(p = 0.0034), demonstrating a higher rate of increase in
leptin levels in the GnRHa/FSH group.
Discussion
Evidences have suggested a relationship between leptin
and the hormones of hypothalamic – pituitary- ovarian
axis [9,19-21]. In this study, we analyzed the relationship
between leptin and estradiol and FSH, in the absence of
interferences of other pituitary and ovarian hormones,
due to suppression of pituitary function after administra-
tion of GnRHa.
Patients selected in this study were submitted to con-
trolled ovarian hyperstimulation for in vitro fertilization
treatment (GnRHa/FSH group) or to oocyte donation
treatment (GnRHa/E2group). As expected, patients
included in the GnRHa/E2 group had had higher mean
age. These patients were enrolled in a program of egg
donation due to the history of low or no ovarian re-
sponse, usually associated with the increase of age.
Regarding obesity, the two groups showed the same pro-
portion of obese patients, thus excluding bias for compari-
son between them. When we evaluated the variation in
leptin levels according to BMI, the results showed that
obese patients had serum leptin levels significantly higher
than those of non-obese, both before and after treatment.nd after treatment
p E2 before treatment E2 after treatment p
0.0001 16.8 ± 7.8 1440.4 ± 1122.6 0.0001
(9 – 29) (200–5150)
0.0079 13.0 ± 6,6 937.9 ± 552.7 0.0001
(9–29) (108 – 2306)
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ously [22]. Although the mean age of both groups was dif-
ferent, it has been previously demonstrated that there is
no difference in levels of serum leptin between young and
postmenopausal women [23].
Pre-treatment and post-treatment evaluations showed
that serum levels of estradiol significantly increased in
both groups after treatment. These results were
expected, since patients presented hypoestrogenism be-
fore treatment due to the use of GnRH analogue and
after were submitted to controlled ovarian stimulation
or to the use of estradiol for endometrial preparation.
When comparing the serum levels of estradiol detected
after treatment in the two groups, we observed signifi-
cantly higher levels in the GnRHa/FSH group, due to
the response to the ovarian stimulation. In the GnRHa/
E2 group, patients received fixed doses of estradiol valer-
ate, thus the levels of estradiol detected in serum reach a
threshold corresponding to the administered dose.
It is not a consensus whether estradiol interfere with
leptin levels. Some studies show that estradiol increases
leptin levels in women with normal menstrual cycles
[24]. In another study it is shown that estrogen therapies
in postmenopausal subjects do not influence serum lep-
tin concentrations [25], and in patients with PCOS, ethi-
nyl estradiol and drospirenone do not increase leptin
levels for a 3-month period [26].
With regard to the evaluation of leptin, we also
observed a significant increase in its serum levels after
treatment, in both groups. These findings demonstrate,
for the first time, an elevation of serum leptin levels sec-
ondary to the increase in estradiol, in the absence of in-
fluence of any other ovarian or pituitary hormone
(GnRH dependent), suggesting a direct correlation be-
tween these hormones and a role of estradiol in stimu-
lating the production or the release of leptin. We
hypothesize that an increase in ob gene (responsible for
leptin synthesis by adipocytes) expression induced by es-
tradiol could be the responsible for these results. An-
other possible mechanism is a leptin gene promoter
activation through selective regulation via estrogen
receptors [27].
Similar results have already been obtained with women
submitted to controlled ovarian stimulation for IVF
without the use of GnRHa [20,28,29]. However, differ-
ently from our work in which women had pituitary sup-
pression, patients included in these studies were
subjected to the influence of ovarian and pituitary hor-
mones, which could interfere with or bias the results.
Although serum levels of leptin were similar in both
groups after treatment, the leptin rate was significantly
higher in the group of patients treated with rFSH when
compared to the group treated with estradiol. This result
can be explained by the higher levels of estradiol observedin this group after treatment. However, we cannot exclude
the possibility of a direct action of FSH on the production
of leptin, through a possible ovarian production or an in-
direct interference in the synthesis of this hormone by adi-
pocytes, through other ovarian substances [30].
This issue is, however, subject of controversy. On the
one hand, it has been shown that leptin levels of women
in menopause are lower than those of women in
menacme [31]. As in menopause endogenous levels of
FSH are very high, these data raise doubt as to whether
FSH indeed stimulates the production of leptin. On the
other hand, other authors [11,30,32] showed the pres-
ence of leptin receptor in ovarian follicles, and the ex-
pression of leptin mRNA in granulosa and cumulus
oophorus cells. It is possible that the influence of FSH
on the ovarian production of leptin occurs only in the
presence of follicles, thus not occurring in menopause.
Conclusions
This study demonstrates a strong correlation between
serum levels of estradiol and leptin, suggesting that es-
tradiol is an important regulator of leptin production.
These results may contribute to a better understanding
of the interaction between metabolic processes and phe-
nomena involved in reproduction. Further investigation
is required to establish the role of FSH on the raising of
leptin levels.
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